Evidence map›Paper›PMID 41374970›Full record

ReviewCancers2025

KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?

Kamila Krupa, Marta Fudalej, Hanna Miski, Emilia Włoszek, Marta Szymczak, Anna Badowska-Kozakiewicz, Aleksandra Czerw, Andrzej Deptała

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kamila KrupaStudents' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.ORCID 0009-0006-1122-6445
Marta FudalejDepartment of Oncological Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.ORCID 0000-0001-8665-2875
Hanna MiskiStudents' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
Emilia WłoszekStudents' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
Marta SzymczakStudents' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
Anna Badowska-KozakiewiczDepartment of Oncological Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
Aleksandra CzerwDepartment of Health Economics and Medical Law, Medical University of Warsaw, 02-091 Warsaw, Poland.ORCID 0000-0002-6189-6678
Andrzej DeptałaDepartment of Oncological Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.ORCID 0000-0003-2640-2043

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a five-year survival rate of 3-15% and limited effective treatment options for most patients. Approximately 5-10% of cases are wild-type KRAS and are more likely to harbor rare alterations, including gene fusions involving anaplastic lymphoma kinase (

Indexed as

BRAF mutationsgene amplificationsgene fusionsgermline mutationsprecision oncologywild-type KRAS

Identifiers

PMID41374970
PMCPMC12691089

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.